[144] Ascendis Pharma A/S SEC Filing
Ascendis Pharma A/S filed a Form 144 reporting a proposed sale of 19,460 ordinary shares on 05/11/2026 through Citigroup Global Markets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ascendis Pharma A/S filed a Form 144 reporting a proposed sale of 19,460 ordinary shares on 05/11/2026 through Citigroup Global Markets. The filing shows an aggregate value of $4,641,021.92 and lists the seller as a Share Plan Account tied to Ascendis Pharma A/S; the method is labeled Compensation.
The excerpt also records a prior sale of 10,277 shares on 03/02/2026 with an aggregate amount of $2,407,985.38 in the past three months.
Insights
Form 144 notifies the market of an intended sale by a company-related share plan account.
The filing lists 19,460 ordinary shares proposed to be sold on 05/11/2026 through Citigroup Global Markets, labeled as Compensation. Form 144 is a notice required when insider holdings are to be sold under Rule 144 or similar resale conditions.
Timing and exact settlement mechanics are not shown in the excerpt; subsequent broker reports or Form 4/Form 5 filings may provide completed sale details.
AI-generated analysis. How Rhea-AI works. Not financial advice.